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Can We Learn From Viruses How to Prevent Type 1
Diabetes?
The Role of Viral Infections in the Pathogenesis of Type 1
Diabetes and the Development of Novel Combination
Therapies
Matthias von Herrath
We will take a journey from basic pathogenetic mechanisms
elicited by viral infections that play a role in the develop-
ment of type 1 diabetes to clinical interventions, where we
will discuss novel combination therapies. The role of viral
infections in the development of type 1 diabetes is a rather
interesting topic because in experimental models viruses
appear capable of both accelerating as well as decelerating
the immunological processes leading to type 1 diabetes.
Consequently, I will discuss some of the underlying mech-
anisms for each situation and consider methods to investi-
gate the proposed dichotomy for the involvement of viruses
in human type 1 diabetes. Prevention of type 1 diabetes by
infection supports the so-called “hygiene hypothesis.” In-
terestingly, viruses invoke mechanisms that need to be
exploited by novel combinatorial immune-based interven-
tions, the ﬁrst one being the elimination of autoaggressive
T-cells attacking the -cells, ultimately leading to their
immediate but temporally limited amelioration. The other
is the invigoration of regulatory T-cells (Tregs), which can
mediate long-term tolerance to -cell proteins in the pan-
creatic islets and draining lymph nodes. In combination,
these two immune elements have the potential to perma-
nently stop type 1 diabetes. It is my belief that only
combination therapies will enable the permanent preven-
tion and curing of type 1 diabetes. Diabetes 58:2–11, 2009
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t is a great honor for me to receive this year’s
American Diabetes Association Outstanding Scien-
tiﬁc Achievement Award, and I would like to express
my sincere gratitude to my peers.
What do we know about type 1 diabetes? Well, we can
be pretty certain that it is an autoimmune disease. Data
from partial pancreas transplants between monozygotic
twins showed that the nondiabetic pancreas was rapidly
destroyed following transplantation (1) and was accompa-
nied by inﬁltration of the islets, called insulitis, which is
indicative of a strong autoreactive response, in the af-
fected diabetic twin who received the transplant. In addi-
tion, autoantibodies to -cell antigens precede the clinical
onset of hyperglycemia and can predict the risk of devel-
oping diabetes (2,3). It is, however, still unclear what
causes this autoreactivity to begin with. In addition to a
strong genetic component, environmental factors, such as
viral infections, lifestyle, and nutrition, have been implicated.
One noteworthy and striking observation in human
type 1 diabetes is that the degree of islet inﬂammation is
rather mild, that is, only a small percentage of islets are
affected, especially in comparison with animal models.
Pipeleers and colleagues (4) found that only 3–4% of all
islets in pre-diabetic patients are affected by insulitis, a
percentage that increased to somewhat higher levels at
the time of diabetes diagnosis. Although the pathoge-
netic implication of this low degree of inﬂammation is
unclear, it might be important in understanding how
viral infections, as an additional factor, might contribute
to the disease process. Thus, there are many open
questions, some of which we will need to answer in
order to cure this terrible disease. Usually, and this is
also the case for our group, animal models are utilized
to better understand these and other immunological
processes in type 1 diabetes pathogenesis as well as to
deﬁne novel interventions. However, translation of at
least some of the ﬁndings to human type 1 diabetes has
been frustrating and ineffective. In this presentation, I
will touch on several of the aforementioned issues and
delineate present and future strategies that could help
improve our mechanistic understanding and transla-
tional successes.
Current perspectives in the prevention or cure for
type 1 diabetes. What are our current perspectives of
treating or preventing type 1 diabetes and what are the
projected timelines? The most basic approach and also
ultimate goal is to tackle the disease at its root, to
eliminate the cause for type 1 diabetes. This could theo-
retically occur by genetic modiﬁcation of genes that
predispose an individual to type 1 diabetes, or the prod-
ucts of those genes, as well as by eliminating environmen-
tal factors, such as those being studied in The
Environmental Determinants of Diabetes in the Young
(TEDDY) trial. This has proven to be a very complicated
approach, as we have learned over the past two decades
that type 1 diabetes is a polygenetic and multifactorial
disease (5–9). We now know that many genes, protective
as well as enhancing, contribute to the development of
type 1 diabetes, which makes it exceedingly difﬁcult to
therapeutically modify all of their products in a suitable
way. From the studies of George Eisenbarth, it is clear
that, in addition to the genetic predisposition, other envi-
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of type 1 diabetes (2,3). Among them, viral infections are
of signiﬁcant interest, and their potential roles will be
discussed later on. It is therefore possible that multiple
and unique pathways can lead to type 1 diabetes and that
the pathogenesis of the disease is heterogeneous in nature.
Thus, eliminating or modifying all of the factors that cause
type 1 diabetes will be difﬁcult, unless the ﬁeld can focus
on a few key molecules absolutely essential for type 1
diabetes development.
In our efforts to ﬁnd a cure, especially for those already
afﬂicted with type 1 diabetes, an unlimited -cell source is
needed, perhaps derived from stem cells, to make islet
transplantation more feasible in general (10–21). At
present, despite the signiﬁcant progress in developing
functioning -cells from stem cells, an insufﬁcient mass of
functional -cells can be generated in vitro. However, in
the pre-diabetic patient, a number of endogenous -cells
are still functional, thus -cell augmentation may be one
way to achieve success.
Reﬁning current islet transplant protocols is also impor-
tant for the future success of islet transplantation. At
present, islet grafts are lost after 6 months to 4 years due
to reemerging autoaggressive immune responses. Recent
studies by Monti and Roep (22,23) have demonstrated that
indeed the -cell protein-speciﬁc autoimmune response is
the main problem in islet graft loss—not the allo-speciﬁc
immune response—and that the number of preexisting
autoreactive T-cells correlates with islet graft loss.
From these investigations, we can conclude that in
order to prevent and cure recent-onset type 1 diabetes,
there is an absolute need for the permanent suppression of
autoaggressive T-cell responses. A possible way in which
this might be achieved is through immune-based and/or
combinatorial therapies, which are being explored in
ongoing clinical trials. The realization from recent studies
that autoimmunity in type 1 diabetes can recur despite
slowing of disease progression, for example after admin-
istration of anti-CD3 to patients with recent-onset type 1
diabetes (24,25) or even after the nonmyeloablative bone
marrow transplants that were attempted in Brazil (26),
underscores an important dilemma: the necessity for du-
rable and speciﬁc immune suppression of islet autoimmu-
nity while simultaneously preserving the patients’ immune
function. In my opinion, this will only be possible by
strengthening the body’s own -cell–speciﬁc, immune reg-
ulatory response.
Viral infections as a trigger or enhancer of type 1
diabetes? Let’s venture into an area that has preoccupied
us for 10 years now: How do viral infections inﬂuence
the development of type 1 diabetes? I will ﬁrst discuss
the current evidence in humans and mice that supports the
hypothesis that viruses do in fact trigger or enhance the
disease process. It is known that viruses, for example
Coxsackie B, Rubella, and mumps, can directly infect and
lyse -cells (27–29). This has been demonstrated by Not-
kins and Yoon (29,30) in 1984, where infection with
Coxsackie B4 led to fulminant type 1 diabetes in a child
and a mouse model. However, epidemiological evidence
indicates that such rapid cases of type 1 diabetes are
relatively uncommon. Our own studies published in 2004
(31) have shown that molecular cross-reactivity or “mo-
lecular mimicry” between viral and -cell antigens is
unable to precipitate type 1 diabetes in a healthy animal.
These data indicate that although viral infections have the
potential to lyse -cells, they do not commonly, in the
absence of a vulnerable immune system, mediate onset of
type 1 diabetes. If viral infections can be considered
unlikely to commonly cause type 1 diabetes in humans by
lysing all -cells rapidly without participation of the im-
mune system, what could their role in the diabetogenic
process be?
Let me propose a concept to you that was brought forth
by us and which might be called the “fertile-ﬁeld” hypoth-
esis, a termed coined by my collaborator, Lindsay Whitton
(32). It goes like this: We know, as mentioned previously,
that genetic predisposition probably accounts for the
development of anti-islet autoimmunity, but not type 1
diabetes, in individuals at risk. What if certain viral infec-
tions that target the islets or pancreas create a “fertile
ﬁeld” for preexisting islet autoimmunity, resulting in its
augmentation, increased -cell destruction, and ultimately
type 1 diabetes? Can we experimentally deﬁne the viral
factors that can push a pre-diabetic or susceptible animal
over the brink and cause type 1 diabetes? I want to share
with you now some experimental data that supports this
concept.
As seen in Fig. 1, which shows data from Francesco
Dotta’s laboratory (33), major histocompatibility complex
(MHC) class I upregulation (left panel) and interferon-
production (right panel) is detected in human islets that
otherwise show absolutely no signs of immune inﬁltration.
Although Dotta et al. provide strong evidence for presence
of Coxsackie virus proteins in these islets, it is still unclear
whether this is always associated with the presence of
viral genomes in the islets or -cells. What is striking about
this ﬁnding is that, usually, MHC molecules and interfer-
ons are only upregulated in the context of signiﬁcant
inﬂammation or as a direct result of viral infection of a
cell. The fact that no insulitis is present in these human
islets but elevation of interferon- and MHC class I expres-
sion is observed presents a strong argument for the
possibility that a viral infection that has already infected
the -cells and persists. Interferons and MHC class I
molecules are usually rapidly downregulated once inﬂam-
mation ceases or an infection has been cleared, but not
when an infection is persistent. Currently, our team and
others are attempting to reproduce and extend these
ﬁndings using freshly frozen human pancreatic specimens
from pre-diabetic and diabetic individuals who had acci-
dental deaths (34).
In experimental animal models we can now ask the
question, what are the immunological consequences of the
FIG. 1. Upregulation of MHC class I molecules and interferon- is
found in human islets in the absence of immune inﬁltration—a viral
signature? Histopathology demonstrating MHC class I upregulation
(left panel) and interferon- production (right panel) is detected in
human islets that otherwise show absolutely no signs of immune
inﬁltration, similar to healthy islets (control, center panel). IFN,
interferon; T1D, type 1 diabetes. (Reprinted and adapted with permis-
sion from ref. 33.)
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studies followed the expression level of MHC class I on
-cells in an animal model of virally induced/enhanced
diabetes (35). We assessed MHC class I levels in a normal
B6 mouse following a viral infection, where no signiﬁcant
numbers of autoreactive CD8
 T-cells were present or
activated, and compared them with MHC class I levels in
-cells of a transgenic animal (RIP-GP), which develops
type 1 diabetes following a viral infection and in which
autoreactive CD8
 T-cells that recognize a protein on
-cells are being generated (36). In the B6 mice, the viral
infection lasts for about a week and affects the pancreas,
leading to a 10- to 50-fold increase in MHC class I
expression on -cells. Importantly, this increase is tran-
sient and recedes to baseline after the virus infection has
been cleared. In contrast, in the transgenic RIP mice that
develop diabetes, and where the -cells express a protein
that is recognized by autoaggressive CD8
 lymphocytes,
MHC class I expression increased more than 100-fold
above baseline and remains high. Based on these observa-
tions, we asked whether this upregulation of MHC class I
molecules plays a role in the recognition and destruction
of -cells by the immune system. This is an important
question, since MHC class I restricts CD8
-mediated kill-
ing of target cells. Only -cells that expressed virally
induced high levels of MHC class I were killed in vitro by
autoreactive CD8
 cytotoxic T-cells. -Cells with basal
levels of MHC class I were invisible to immune recogni-
tion. We can conclude from these ﬁndings that, under
normal physiological circumstances, when there is no
inﬂammation present in islets, -cells are invisible to
CD8
-mediated killing. In contrast, if MHC is being up-
regulated through inﬂammation, a viral infection, or both,
-cells become susceptible or “unmasked” to immune-
mediated attacks. This is reﬂected by the rapid develop-
ment of type 1 diabetes in this virally induced type 1
diabetes animal model.
The upregulation of MHC class I in this model is caused
by many inﬂammatory factors, but the main mediators are
interferons. Consequently, the presence of interferons and
upregulation of MHC class I is detrimental for the -cell.
Viruses can cause this elevation of interferons and upregu-
lation of MHC class I, and if they are directly present in the
pancreas or islets, they can be considered prime suspects
in enhancing the diabetogenic process. It is noteworthy
that the virus we used, lymphocytic choriomeningitis virus
(LCMV), rarely infects -cells directly, which demon-
strates that direct infection of -cells is not needed. From
the ﬁndings I have just described, we can make a good
case that certain pancreatotropic virus infections do not
directly cause, but rather substantially contribute to, the
pathogenesis of type 1 diabetes by the inﬂammatory
reaction that they induce by the host.
In summary, we have generated an interesting animal
model that emulates what could occur in humans. Viral
infections can cause strong inﬂammation and/or upregu-
lation of MHC class I molecules and interferons. In animal
models, for virally induced type 1 diabetes, MHC class I
upregulation on -cells is a prerequisite for their recogni-
tion and demise by killer CD8
 T-cells. This is a transient
process and recedes to baseline once the virus is cleared.
Human islets can also express MHC class I and interfer-
ons, and this is seen even in the absence of an inﬂamma-
tory inﬁltrate. Thus, infections, although rarely able to
directly cause type 1 diabetes, might act as providers of a
“fertile ﬁeld” to precipitate type 1 diabetes in individuals
genetically at risk.
Prevention of type 1 diabetes through viral infec-
tions. What about the ﬂipside of this coin, that is, the
possibility that viral infections and other types of infec-
tious diseases would actually prevent type 1 diabetes? At
ﬁrst, this seems counterintuitive because of the aforemen-
tioned data indicating that viruses can be strong inducers
of inﬂammation. However, emerging experimental evi-
dence from various animal models has taught us other-
wise. I will discuss some of the evidence and underlying
mechanisms in the following examples.
New unpublished data from us and published work from
others (37–39) support the so-called “hygiene hypothesis,”
which implies that type 1 diabetes is a disease of the more
industrialized countries because lesser numbers of infec-
tions occur and the immune system has therefore less
opportunity to be properly trained for its main task, which
is host defense. For example, in our laboratory, we in-
fected two completely different pre-diabetic type 1 diabe-
tes mouse models, the NOD and the RIP-LCMV (36), with
Coxsackie B3. This virus has been shown to systemically
infect mice and has been epidemiologically associated
with human type 1 diabetes. The Cox B infection usually
lasts 10 days and involves the pancreas, but rarely the
islets. Interestingly, acceleration of diabetes is only seen in
some instances and depends on the timing of infection
(40–43), for example, when Coxsackie B3 is given to
10-week-old NOD mice or RIP mice 7 days post triggering
of the diabetogenic response. Interestingly, it is important
to note that an equally common outcome for viral infection
is the lowering of diabetes penetrance. I would now like to
discuss some impressive data supporting one of the un-
derlying mechanisms for viral prevention of type 1 diabe-
tes and then discuss some of the other potential
mechanisms in a brief overview.
In recent unpublished observations, we discovered that
infection of NOD mice could lead to invigoration of Tregs.
Instead of enhancing immune function and exerting effec-
tor functions such as killing of infected cells or inducing
interferon production (44–47), Tregs can turn immune
responses off. They do this through a variety of mecha-
nisms in vivo, many of which involve the secretion of
immune modulatory cytokines such as interleukin (IL)-10,
IL-4, or transforming growth factor (TGF)-. In our study,
NOD mice that usually develop spontaneous autoimmune-
mediated diabetes were infected with LCMV, which is
cleared after 7 to 10 days. We observed a signiﬁcant
decrease in the incidence of type 1 diabetes, down from
about 75% to about 15%. Tregs were subsequently isolated
from these NOD mice several weeks after the protective
viral infection and transferred into nonmanipulated naive
NOD recipient mice during the pre-diabetic phase. Only
the sorted Tregs from mice that had undergone the viral
infection were potent enough to protect recipient NOD
mice from development of diabetes. We conclude that the
systemic viral infection invigorated the Tregs.
To understand the mechanism of protection, ﬂuores-
cence-activated cell sorting analysis of Tregs from mice
that had received the LCMV virus was compared with that
of Tregs from nonmanipulated mice. The mice that had
been infected produced a 10-fold increase in TGF-.W e
then investigated whether in vitro suppression by virally
invigorated Tregs was dependent on TGF- by using
cytokine blocking antibodies. Indeed, their suppressive
function was decreased in the absence of TGF- by about
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Tregs in vivo. Interestingly, the transfected Treg function
was enhanced to the same level as the suppressive capac-
ity seen in virally invigorated Tregs. We therefore con-
clude, from these ﬁndings, that viral infections enhance
Treg activity in part by augmenting TGF- production.
Recent ﬁndings from our lab have demonstrated that this
occurs in a Toll receptor-2–dependent fashion (C. Filippi
and M.v.H., unpublished observations).
To summarize what we have learned so far regarding the
mechanism by which viral infections can inhibit a diabe-
togenic response, please see Fig. 2. TGF- augmentation
of Tregs is not solely responsible for virally mediated
prevention of type 1 diabetes. It turns out that there are
important general mechanisms that occur simultaneously,
while the virus infection is ongoing. Based on our ﬁndings,
these are associated with the viral induction of PD-1L and
tumor necrosis factor (TNF)- (31). Both molecules have
been shown to downmodulate immune responses and are
important for the attrition of the antiviral immune re-
sponse, when the viral infection is being cleared (with the
purpose to limit excess immunopathology). Indeed, what
happens after a viral infection, and this mechanism holds
true for Coxsackie B viruses and other systemic infec-
tions, is that not only are the antiviral T-cells being
eliminated, but PD-1L and TNF- are mediating the by-
stander death of autoaggressive T-cells. This aspect of the
mechanism results in a delay in the progression to type 1
diabetes but not a reduction in the overall incidence. The
invigoration/activation of Treg cells is ultimately respon-
sible for the observed reduction in incidence of type 1
diabetes in our model systems. Combined, these cytokine
effects result in reduced incidence and delay of type 1
diabetes. These ﬁndings also illustrate rather elegantly
that there are two components needed to prevent or cure
type 1 diabetes therapeutically: 1) elimination of autoag-
gressive T-cells and 2) augmentation of Tregs to achieve
long-term tolerance.
Treatment of type 1 diabetes with novel combinato-
rial therapies. We will now discuss potential combina-
tion therapies in recent-onset type 1 diabetes. As indicated
above, there are multiple immune-modulatory steps re-
quired for the ultimate protection against type 1 diabetes
as well as protection against progression of disease.
Because of the multifaceted nature of this disease, a
monotherapy will not be sufﬁcient to combat type 1
diabetes. The best approach is to use a combination
therapy (Table 1), with the goal being the early elimination
of autoaggressive T-cells followed by inducing long-term
tolerance through induction of regulatory T-cells. Combi-
nation therapies consist of a short-acting systemic immu-
nosuppressant and an antigen-speciﬁc vaccine that
synergize to enhance efﬁcacy in preventing or delaying the
onset of clinical type 1 diabetes. Long-term systemic
immunosuppression is therefore not necessary, thus re-
ducing deleterious side effects and decreasing the poten-
tial for infections and cancers (48). In contrast, direct
administration of cytokines results in more side effects,
and the cytokine half-life in blood is very short, necessi-
tating repeated administration (49,50). Drugs such as
anti-CD3 also have systemic side effects, and their efﬁcacy
so far has been limited to reducing the decline in C-peptide
production in patients with early-onset diabetes (24,51). In
turn, vaccination with -cell auto-antigens alone has lim-
ited efﬁcacy, albeit no side effects (52–54). However, as
shown by us in animal models, efﬁcacy can be increased
through synergistic effects, which allows for a dose reduc-
tion of the systemically acting immunosuppressant (anti-
CD3) and therefore increases the safety margin of the
intervention (55). In summary, a potential, yet potent
combinatorial therapy for type 1 diabetes, would consist
of a systemically acting antibody such as anti-CD3 with an
islet antigen–speciﬁc vaccine to augment Tregs. This cock-
tail would have limited side effects and enhance efﬁcacy
signiﬁcantly.
I will now discuss islet antigen–speciﬁc Tregs and their
contribution toward establishing long-term tolerance and
thus protection against the development of type 1 diabe-
tes. To understand autoreactive islet antigen–speciﬁc
Tregs, one has to consider that any adaptive immune
response consists of different classes of responses such as
pro-inﬂammatory and anti-inﬂammatory, and these com-
bined responses constitute a process in equilibrium. This
equilibrium can be shifted, however, if either effector or
regulatory responses are increased. The result of this shift
in equilibrium is either enhanced inﬂammation or resolu-
tion of the process. Therefore, it follows that immune
regulation is context, and likely organ, dependent. Tregs
will likely have as many functions and phenotypes as T
effector (Teff) cells. Key effector molecules produced by
Tregs are cytokines such as IL-10, TGF-, and FoxP3,
which can modulate the interaction of Teff with antigen-
presenting cells (APCs) and are therefore frequently cru-
cial in mediating tolerance. Because of this Treg/Teff
balance, it is logical that any inﬂammatory reaction in-
volved in to the pathogenesis of type 1 diabetes will
contain some autoreactive regulatory cells that recognize
islet antigens. In individuals who develop diabetes, the
existing Tregs are not sufﬁcient in numbers or activities to
suppress the diabetogenic response, but modulation of
FIG. 2. Conclusions and mechanistic hypothesis: How viral infections
can stop type 1 diabetes. TGF- augmentation of Tregs is not solely
responsible for virally mediated prevention of type 1 diabetes. The
viral induction of both PD-1L and TNF- has been shown to downmodu-
late immune responses and are important for the attrition of the
antiviral immune response, when the viral infection is being cleared.
PD-1L and TNF- also mediate the bystander death of autoaggressive
T-cells.
TABLE 1
How combination therapies will help in translating antigen-
speciﬁc immunotherapy to induce Tregs
1. Enhancing efﬁcacy while reducing unwanted systemic
side effects
2. Choosing the correct islet antigen
3. Choosing the right dose of antigen
4. Choosing optimal time for intervention  identifying
ideal target group (pre-diabetic, recent onset)
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IL-10, IL-4 or TGF- could be a unique and powerful
opportunity to augment the body’s own Treg response in
order to suppress islet destruction and achieve long-term
tolerance. In my opinion, augmenting autologous Tregs is
the only approach that could be used to treat or revert type
1 diabetes with sufﬁciently low side effects as well as
long-term duration. Furthermore, such autologous Tregs
could be induced by mucosal or DNA vaccination (56,57),
which would be universally applicable and would not
involve expensive or complicated techniques.
Induction of islet antigen–speciﬁc Tregs to achieve
long-term tolerance. Some of the advantages of Treg
activation are depicted in Fig. 3. When an APC presents
-cell proteins to an autoreactive Treg following, for
example, mucosal immunization with insulin or subcuta-
neous immunization with GAD, autoreactive T-cells that
recognize this protein, among them Tregs, become acti-
vated, proliferate, and circulate throughout the body. The
activated cells will reach various organs and scan these for
the antigentic protein, as shown to occur in the pancreatic
draining lymph nodes and sometimes the islets in type 1
diabetes animal models (53,58). The number of cells is
further augmented by proliferation within the lymph node
or pancreatic islets, and soluble mediators secreted by the
Tregs in these localized areas will now have multiple
beneﬁcial effects. Cytokines such as TGF-, IL-4, and IL-10
have the potential to modulate or temper the activity of
antigen-presenting and destructive islet effector cells.
Seminal to this discovery is that these events occur locally
in the pancreatic lymph node or islets, thus circumventing
systemic immunosuppression by the host. Furthermore,
regulation of the effector cells takes place, regardless of
their antigentic speciﬁcity. This well-documented phenom-
enon was termed “bystander suppression” by Howard
Weiner (54). Thus, and this is conceptually very important
for therapies involving augmentation of Tregs, one does
not have to know the initiating or “driving” antigens to
suppress type 1 diabetes with autoreactive Tregs.
These activated Treg cells have another advantage in
that they can mediate “infectious tolerance” and work as a
tag team. Mechanistically, Tregs can entice APCs within
the islets or pancreatic lymph node to induce and augment
other types of Tregs. This phenomenon was ﬁrst described
by Hermann Waldman and Polly Matzinger, and Oral Alpan
had a very elegant article on this topic (59–61). Thus,
Tregs are a very attractive option to induce long-term
tolerance while avoiding systemic side effects, and there is
substantial evidence from animal models to support this
concept.
Obstacles to translating antigen-speciﬁc therapies
involving Tregs to the clinic. We have to ask the
questions, what has hampered the translation of antigen-
speciﬁc Treg therapies to the clinic and what can we do
about it? You will see that combination therapies will
likely provide the answers to these questions. For in-
stance, the treatment of recent-onset diabetes can be
mediated by a combinatorial therapy that will induce a
protective immune response as well as provide long-term
tolerogenic effects. However, there still exist several hur-
dles to overcome in therapeutic translation to the clinic.
Figure 4 shows a representative histological picture for
long-term tolerance following induction of Tregs with oral
insulin in the mouse model. The left panel shows a
completely destroyed islet of a diabetic RIP-LCMV mouse.
The right panel shows a representative image of mild
insulitis commonly found in mice protected from type 1
diabetes onset after administration of oral insulin during
the pre-diabetic phase. Here, the -cells are mostly intact,
and the immune cells are located at the periphery but not
within the islet. Some of the cells in the periphery do have
regulatory activity, as shown by enzyme-linked immuno-
spot analysis (62). Despite these promising results with
-cell antigen vaccinations, there are still signiﬁcant ques-
tions that need to be addressed before clinical trials are
initiated. Several of these issues are delineated in Table 1
and include predicting which islet antigen is optimal to use
for an individual patient, deﬁning the right dose of -cell
antigen for immunization, and choosing the proper time
for intervention. However, these aspects may become less
problematic as initially thought, when taken into context
with a combinatorial treatment rather than as a mono-
therapy. The means by which combination therapy will
address these concerns are described below and will be
illustrated with some examples from experimental data,
demonstrating how combination therapies will help.
FIG. 3. Bystander suppression by Tregs: Tolerance tag team? When an
APC presents -cell proteins to an autoreactive Treg following, for
example, mucosal immunization with insulin or subcutaneous immuni-
zation with GAD, autoreactive T-cells that recognize this protein,
among them Tregs, become activated, proliferate, and circulate
throughout the body. The activated cells will reach various organs and
scan them for the antigentic protein, as shown to occur in the pancre-
atic draining lymph nodes and sometimes the islets in type 1 diabetes
animal models. The number of cells is further augmented by prolifer-
ation within the lymph node or pancreatic islets, and soluble mediators
secreted by the Tregs in these localized areas will now have multiple
beneﬁcial effects and mediate long-term tolerance by suppressing the
aggressive autoreactive effector response.
FIG. 4. Long-term tolerance following induction of regulatory T-cells
with oral insulin: Histological representation of long-term tolerance
following induction of Tregs with oral insulin in the mouse model.
Shown are a completely destroyed islet of a diabetic RIP-LCMV mouse
(left panel) and mild insulitis commonly found in mice protected from
type 1 diabetes onset after administration of oral insulin during the
pre-diabetic phase (right panel). In these images, the -cells are
mostly intact and the immune cells are located at the periphery but not
within the islet.
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are suited to induce Treg activation, and efﬁcacy depends
on the genetic background of the host. For example,
immunization with insulin, but not GAD, protects NOD
mice during the pre-diabetic phase (D. Bresson and M.v.H.,
unpublished results). Although not shown, it is important
to know that efﬁcacy of these antigens is reversed when
used in a mouse with a different genetic background, such
as in B6 mice. In this case GAD immunization protects
better than insulin. In the majority of genetic backgrounds,
however, protection can be enhanced by co-immunization
with cytokine expressing plasmids (63), indicating that
combination therapy with immune modulatory com-
pounds will not only be beneﬁcial but also, in some cases,
prevent the generation of insulin auto-antibodies (M.v.H.
and G. Eisenbarth, unpublished results). Thus, efﬁcacy of
antigen-speciﬁc induction of Tregs depends on the individ-
ual genetic background, the context in which antigen
presentation occurs, and the extent of activation of the
preexisting Treg repertoire.
The dose of the islet antigen used for induction of Treg
cells also appears to play a crucial role. For example,
orally administered human or porcine insulin, or insulin
conjugated to the cholera toxin B subunit to enhance
efﬁcacy, protects only at intermediate dosages, but not
when low or high amounts of oral antigen are adminis-
tered (64). Such bell-shaped dose-response curves are
common to oral antigens and constitute a major roadblock
for clinical translation because there are no suitable
biomarkers to assess or predict which antigenic dose
might be optimal for a given individual.
It is known from multiple animal studies that protection
from diabetes by induction of Tregs is most effective when
the intervention is done early, not late. Also, the time point
of Treg induction in relation to the diabetogenic response
is of importance. Based on our unpublished data (G.
Fousteri and M.v.H., unpublished results), intranasal pep-
tide treatment can lead in some experiments to signiﬁcant
acceleration of disease in older mice, whereas similar
peptide treatments in younger mice were reported to have
signiﬁcant protection from diabetes. The occasional accel-
eration of the disease observed after immunotherapy in
older mice is indicative of a preexisting pool of activated
effector cells, which cannot be turned off by a monothera-
peutic Treg-inducing vaccination process alone. This del-
eterious negative outcome, however, can be overcome by
the use of a combination therapy or use of suitable
adjuvants, for example, incomplete Freund’s adjuvant.
This mechanism ensures that regulatory, not islet-attack-
ing, effector T-cells are being generated following immu-
nization. In fact, immunization in the presence of
adjuvants as a type 1 diabetes therapeutic is currently
being tested in an ongoing clinical trial in Boston (65).
Thus, although promising in terms of establishing long-
term tolerance, there are signiﬁcant hurdles that need to
be overcome before induction of islet antigen–speciﬁc
Tregs can be brought to the clinic setting. These include
ﬁnding the correct dose to induce and not delete Tregs,
deﬁning the proper antigen for vaccination or Treg recog-
nition (ideally not an antigen that is already being targeted
by a destructive ongoing immune response), selecting an
appropriate adjuvant or immunosuppressive agent for
co-vaccination, and deﬁning the optimal time in the dis-
ease process for such an intervention. As discussed ear-
lier, one way to circumvent some of these issues would be
to combine the Treg augmentation immunization with a
short-term course of a suitable, systemically acting immu-
nosuppressant or immune modulator. Such a compound
would ideally have two key abilities: 1) to dampen the
destructive response attacking the islets in order to gen-
erate a sufﬁcient window for Tregs to be augmented and 2)
to immunosuppress in such a way that Tregs are not
affected. An example of one such compound is anti-CD3.
Combination therapy of recent-onset type 1 diabetes
using anti-CD3 and immunization with -cell antigens.
Human clinical study results in recent-onset type 1 diabe-
tes treated with non-FC binding anti-CD3 (24,51) have
shown that a 14-day course can delay the decline of
C-peptide in recently diagnosed individuals by 2–3 years.
Herold and coworkers (55) have also shown augmented
Treg responses after anti-CD3 treatment. These results in
conjunction with the success of mouse vaccination studies
using mucosal administration of -cell antigens to induce
adaptive Tregs led to the expectation that their combina-
tion (anti-CD3 and islet antigen vaccines) would result in
long-lasting tolerance. We conducted a proof of principle
mouse trial; we combined a 5-day course of a suboptimal
anti-CD3 dose with intranasal application of a proinsulin
peptide to treat recently diabetic mice using two animal
models, the NOD mouse and the RIP-LCMV mouse (55). In
previous studies, higher doses of anti-CD3 had reverted,
thus cured, type 1 diabetes in both mouse models. With the
current study, the question was whether combination
therapies would result in an increased efﬁcacy of type 1
diabetes reversion with an otherwise suboptimal dose. As
expected from the earlier studies, the proinsulin peptide
alone had no or very limited efﬁcacy in recent-onset
diabetes in both mouse models. Furthermore, a subopti-
mal anti-CD3 dose alone also exhibited very limited efﬁ-
cacy. In contrast, the combination of both anti-CD3 and
proinsulin peptide administration exhibited signiﬁcant
synergy, with a 100% increase in the reversion rate for both
recent-onset hyperglycemia and diabetes. Based on these
encouraging results, other islet antigens were also tested
for their immunomodulatory properties in conjunction
with anti-CD3. Synergy with oral and nasal whole insulin
immunization was observed as well as several DNA vac-
cines expressing insulin or GAD. Some synergy was also
seen in preliminary studies using GAD-Alum administered
subcutaneously. Thus, islet antigen–speciﬁc therapies in
combination with anti-CD3 resulted in a synergistic effect
that increased the reversion rate of recent-onset diabetes
in two different animal models.
In follow-up studies, we were able to deﬁne the under-
lying mechanisms for the above-described synergism and
therefore proceeded to test additional parameters that
were clinically relevant. In Fig. 5A–C, animals that re-
mained diabetic are shown with squares, the animals that
reverted to normoglycemia are shown with diamonds, and
those transiently reverted are shown with triangles. These
data were correlated with age (x-axis) and blood glucose
(y-axis) of the animal at the onset of hyperglycemia and
the start of intervention. The upper panels show the NOD
mice that underwent combination therapy, whereas the
bottom panels portray the animals treated with the mono-
therapy anti-CD3. One striking observation was that re-
gardless of age of diabetes onset, mice with chronically
high blood glucose values were essentially refractory to
the combination therapy (Fig. 5A vs. B). There was an
improved response to the combination therapy when mice
had a lower blood glucose value (Fig. 5B), perhaps when
animals were at an earlier stage of disease progression. We
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from Chatenoud and coworkers in the human anti-CD3
trial (51). If one considers blood glucose values in non–
insulin-treated NOD mice as a correlate of remaining -cell
activity, individuals with high C-peptide values respond
much better to anti-CD3 treatment than those with lower
C-peptide values. It appears that reversion of recent-onset
type 1 diabetes is not possible once -cell mass has
declined beyond a certain point.
The other remarkable clinical correlate discovered was
that younger mice with lower blood glucose levels re-
sponded very well to the combination therapy, as shown in
Fig. 5C. Here, statistics revealed a 75% reversion rate from
type 1 diabetes in the combination therapy–treated mice.
Only a 27% reversion rate was seen in mice treated at
diabetes onset with anti-CD3 alone. The reason for this
phenomenon is not known, but it is possible that younger
mice have better capacity to regenerate -cells after
inception of treatment and thus reestablish euglycemia.
What are the underlying mechanisms for the enhanced
protection in the group that received anti-CD3 and intra-
nasal proinsulin peptide versus monotherapy with either
agent? We have observed increased induction of Tregs that
react to proinsulin and a reduction in CD8
 T-cells speciﬁc
for -cell antigens in both diabetes models treated with the
combination therapy (55). The ability of T-cells isolated
from mice receiving the combination therapy, versus those
treated with anti-CD3 alone, to produce the regulatory
cytokines IL-4 or -10 in vitro in response to the proinsulin
peptide was augmented. Thus, nasal peptide immunization
FIG. 5. A: Essential inﬂuence of age (reﬂects rapidity of diabetogenic
response) and blood glucose value (BGV) (reﬂects remaining islet
mass) at treatment onset. Forty-four percent of the mice with chroni-
cally high BGVs were essentially refractory to the combination therapy.
B: Essential inﬂuence of age (reﬂects rapidity of diabetogenic re-
sponse) and BGV (reﬂects remaining islet mass) at treatment onset.
There is better synergy in mice with higher remaining -cell mass (BGV
<450 mg/dl): 65% of animals with consistently lower blood glucose
(<450 mg/dl) achieved improved synergy with combination therapies.
This lower blood glucose range is indicative of remaining islet mass. C:
Essential inﬂuence of age (reﬂects rapidity of diabetogenic response)
and BGV (reﬂects remaining islet mass) at treatment onset. The best
synergy occurs in mice with higher -cell mass and rapid type 1 diabetes
onset. A 75% reversion rate from type 1 diabetes was observed in
animals receiving the combination therapy. These animals were
younger and had a more rapid type 1 diabetes onset. Only a 27%
reversion rate was seen in mice treated at diabetes onset with anti-CD3
alone. The reason for this phenomenon is not known, but it is possible
that younger mice have better capacity to regenerate -cells after
inception of treatment and thus reestablish euglycemia.
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lead to enhanced islet antigen–speciﬁc production of
immune modulatory cytokines that are known from many
earlier studies to delay or prevent type 1 diabetes. This
strongly indicates that islet-adaptive Tregs were aug-
mented by the combination therapy. In support of the
clinical translation of this ﬁnding was our discovery that
increased numbers of IL-10–positive Tregs at diagnosis
correlated with better glycemic control 3 months later in a
small clinical study (66). Thus, increasing Tregs by vacci-
nation in conjunction with an immunomodulatory as com-
bination therapy might improve glycemic control.
We then took a closer look at the phenotype and further
function of such Tregs in the mouse models. After combi-
natorial treatment, Tregs were FoxP3-positive and the
numbers of CD4
CD25
 Tregs following combinatorial
treatment were signiﬁcantly increased compared with
those treated with anti-CD3 monotherapy alone. Further-
more, when the CD4
CD25
 Tregs were sorted and stim-
ulated with the proinsulin peptide, we again found
increased production of cytokines known to have immune
modulatory or dampening functions (TGF-, IL-10, and
IL-4).
We next wished to understand whether this increased
induction of Tregs in response to the proinsulin peptide
affected the number or activity of autoreactive CD8

lymphocytes known to attack -cells. In both models
treated with the combination therapy versus the anti-CD3
alone, or compared with pre-diabetic mice, a strong reduc-
tion in the number of autoaggressive CD8
 lymphocytes
was seen. The numbers were on average reduced by
threefold compared with those in untreated or pre-diabetic
mice. We would argue that this loss of autoreactive CD8

lymphocytes is the result of proinsulin-speciﬁc Treg-medi-
ated bystander suppression. Indeed, our earlier studies
published in Immunity in 1999 had ﬁrst described this in
mice that received Treg transfers from oral insulin–treated
donors (53). The transfer of 10
5 CD4
 cells from an oral
insulin–treated RIP-LCMV mouse that had been protected
from type 1 diabetes resulted in localized reduction of
autoaggressive CD8
 cells in the pancreatic lymph node
but not other lymphoid sites. The site speciﬁcity of the
regulatory effect is also a clinically important point and is
likely due to the fact that transferred Tregs only proliferate
in the pancreatic lymph node, not in other locations, as
shown by CFSE (carboxyl ﬂuorescent succinimidyl ester)
labeling. We can therefore conclude from these studies
that the antigen-speciﬁc component of our combination
therapy, which is the intranasal administration of the
proinsulin peptide, leads to an augmentation of proinsulin-
speciﬁc adaptive Tregs, which are able to bystander-
suppress autoaggressive CD8
 T-cells. This result was
similar in two distinct diabetes models and lead to en-
hanced prevention of disease, when the induction of Tregs
by the proinsulin peptide was combined with a short-
course anti-CD3 treatment.
It is my personal opinion that only combination thera-
pies and not monotherapies will be able to treat recent-
onset diabetes, and a strong effort should be made to
clinically translate such approaches. Other combinations
of antigenic immunization with systemic immune modula-
tors can be envisioned—ideally, a combination therapy
will consist of an islet antigen–speciﬁc immunization, such
as oral insulin, coupled with a systemic drug that dampens
islet destructive immunity but does not affect Tregs.
Anti-CD3, Rituxan (anti-CD20), Anakinra, and possibly
ATG (antithymocyte globulin) are good candidates for
this.
Future perspectives. I would like to introduce newly
emerging and exciting areas of research that could be
important in translating such approaches more rapidly.
One very interesting new avenue is the use of in silico
modeling, or virtual NOD mice, to predict and narrow
down optimal treatment protocols. We have spent the past
year, thanks to an American Diabetes Association–sup-
ported grant, working with the company Entelos (67),
simulating optimized treatment regimens. In this case,
some interesting and surprising predictions were made,
which we are currently following up to validate with
wet-lab experiments in our laboratory. Entelos generated
a variety of virtual NOD mice and tested under which
experimental conditions most of these would revert to
normoglycemia after recent-onset type 1 diabetes using
anti-CD3 and oral insulin combination therapy. Less than
50% of virtual mice reverted to normoglycemia in these
simulations, when anti-CD3 and oral insulin were given at
the same time. This prediction is fully reﬂected by our
current experimental data, combining anti-CD3 and oral
insulin (D. Bresson and M.v.H., unpublished observations).
Unexpected to us, Entelos’ simulation predicted that the
therapeutic window will be much larger if anti-CD3 is
given after the oral insulin. The delay in anti-CD3 admin-
istration should allow for sufﬁcient time for Treg genera-
tion. We are currently validating this prediction.
Additionally, and in relevance to the ongoing oral insulin
trial DPT-1 (Diabetes Prevention Trial of Type 1 Diabetes),
there is an optimal and bell-shaped dose range for oral
insulin, too frequent insulin dosing is not beneﬁcial, and
few if any mice are predicted to revert from hyperglyce-
mia. In the future, one can imagine that similar predictive
simulations could guide human trial design and deﬁne
optimal dosing regimens, optimal time for testing for
induced T-cells (as biomarkers), and so forth.
In summary, let me share some thoughts about what I
believe will solve the puzzle of type 1 diabetes in the future
(Table 2). Foremost, we will need direct access to human
pancreata to better understand the pathogenesis of the
TABLE 2
Future directions and perspectives
1. We need direct access to human pancreata to better
understand the pathogenesis of the human
disease.
2. We need live imaging data from mouse and human
islets to better understand the kinetics of -cell
death and regeneration (2-photon and other
techniques).
3. We need to have diverse teams that comprise
expertise from immunology, islet physiology, and
complications in order to tackle this disease.
4. We need to make a commitment to test
combination therapies now, before single drugs
have been approved for type 1 diabetes.
5. We need to establish suitable biomarkers that can
predict success of a given intervention.
Longitudinal T-cell studies will be essential,
especially if the process leading to type 1
diabetes turns out to be relapsing-remitting in
nature.
6. The ultimate goal should be an early childhood
vaccine that redirects the immune system
towards tolerance to -cells.
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crucial gaps in human pathogenesis and not vice versa. We
need live imaging data from mouse and human islets to
better understand the kinetics of -cell death and regen-
eration. We have recently been successful at visualizing
autoreactive lymphocytes entering and leaving the islets in
the living animal (K. Coppieters and M.v.H., unpublished
observations). We need to have diverse teams that com-
prise expertise from immunology, islet physiology, and
complications in order to tackle this disease. We need to
make a commitment to test combination therapies now,
before single drugs have been approved for type 1 diabe-
tes. Life-long immunosuppression will be difﬁcult to justify
for type 1 diabetes. We need to establish suitable bio-
markers that can predict success of a given intervention.
Longitudinal T-cell studies will be essential, especially if
the process leading to type 1 diabetes turns out to be
relapsing-remitting in nature. We presented the concept
that Tregs and Teffs might undergo rapid cyclical changes
during type 1 diabetes pathogenesis in a recent Nature
review article (68). The ultimate goal should be an early
childhood vaccine that redirects the immune system to-
ward tolerance to -cells.
Finally, I’d like to conclude with a more general view of
an area of high importance, that is, how do we facilitate
clinical translation of data relevant to type 1 diabetes, and
for that matter, all clinically relevant data? We must
improve the collaboration between academic researchers,
industry, and funding bodies. Unfortunately, there are
divergences that inhibit collaborative efforts. One major
roadblock is the fact that academia is evaluated on indi-
vidual achievements, not necessarily on the ability to work
well in networks or in teams. In translational medicine,
however, sharing of expensive resources, pooling of ef-
forts, and involvement of larger networks is frequently
unavoidable. Another example is the fact that industry is
perhaps motivated too much by proﬁt, which is not always
the best driving force if one considers diseases such as
type 1 diabetes, with a smaller market opportunity. Last,
funding bodies are frequently driven by timeline con-
straints through their constituency—this can result in
unrealistic timelines and, even worse, in cessation of
funding for expensive endeavors after a large amount of
infrastructure, as frequently needed for clinical trials, has
already been created. I would like to leave you with the
thought that we need to work hard and work together to
change some of these paradigms. We will need to create
novel coalitions and synergy and shift some of the existing
paradigms. Evaluation of academic careers will have to
involve factors other than the number and impact of
papers. Treatment of orphaned diseases will require addi-
tional funding and incentives to attract industry. Funding
bodies need to not abandon infrastructure they created
based on time lines dictated by granting mechanisms.
Finally, and most importantly, we all need to work to-
gether more effectively to beneﬁt the health and overall
quality of life of our patients.
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